Tag Archives: Market Access

Market Access is Dead: Patient Access is the New Prescription for Healthcare Marketing

by John Glasspool Paradigms change when questions emerge the old paradigm can no longer answer. Market access has become a buzz word as access to markets is as significant a hurdle to product usage as registration itself. Initially a topic for pharmaceutical companies concerned about volume, it now affects all aspects of healthcare. We believe […]
Posted in Global, Market Access, Strategy | Also tagged , , , , , , , , | 5 Comments

Patients on the Picket Line

Good science can’t be rushed, even when the lives of patients hang in the balance. But regulatory science, and its relationship to a drug’s commercial success or failure, can inadvertently block access to individual patients in their hour of need.
Posted in Biotech, FDA, healthcare, Legal, Market Access, Regulatory, Safety | Also tagged , , , , , , , , , , , | Leave a comment

Compliance Top Driver of Change, Survey Says

Last year, only two percent of the respondents surveyed by Cegedim cited regulatory and compliance issues as a driver of new technology adoption, and six percent said regulatory and compliance was a primary driver of pharmaceutical business model or process change. A lot can happen in a year.
Posted in compliance, Market Access, Strategy | Also tagged , , | Leave a comment

Former EMA Head Back in the Regulatory Saddle

His decade-long tenure as head of the European Medicines Agency (EMA) may have ended, but Thomas Lönngren is already back in the regulatory saddle as a strategic advisor to NDA Group, an independent consulting group focused on reducing wasted drug development costs, ensuring new medicines get to market faster, and “improving the performance of the […]
Posted in Europe, Global, leadership, Market Access, People, pricing, R&D, Regulatory | Also tagged , , , | Leave a comment

What Can Big Pharma Learn From Other Industries in Emerging Markets?

Building a durable base for growth in emerging markets is top line in pharma’s strategy to compensate for slowing sales in the US and Europe.   Key to success is moving beyond the traditional reliance on serving the smallest, most affluent segment of the market to seed critical mass: expanding resources for health, broadening the customer […]
Posted in Emerging Markets, IP, Market Access, Marketing, Strategy | Also tagged | 1 Comment
  • Categories

  • Meta